Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma
Authors
Keywords
-
Journal
Experimental Hematology & Oncology
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-15
DOI
10.1186/s40164-021-00215-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diffuse Large B-Cell Lymphoma
- (2021) Laurie H. Sehn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma
- (2020) Ying Li et al. Journal of Translational Medicine
- Association of tumor mutational burden with age in solid tumors.
- (2020) Zhuang Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression patterns of immune checkpoints in acute myeloid leukemia
- (2020) Cunte Chen et al. Journal of Hematology & Oncology
- Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population
- (2020) Feili Chen et al. Cancer Management and Research
- Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort
- (2020) Nicholas Bevins et al. Journal for ImmunoTherapy of Cancer
- Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
- (2020) Jinchul Kim et al. Frontiers in Oncology
- RDGN-based predictive model for the prognosis of breast cancer
- (2020) Bing Dong et al. Experimental Hematology & Oncology
- The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
- (2020) Yanhui Chen et al. Experimental Hematology & Oncology
- High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study
- (2020) Eva-Maria Talvitie et al. NEOPLASIA
- A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression
- (2020) Jialin Ma et al. Biomarker Research
- Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
- (2019) Bixia Tang et al. Journal of Hematology & Oncology
- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- Mortality of lymphoma and myeloma in China, 2004–2017: an observational study
- (2019) Weiping Liu et al. Journal of Hematology & Oncology
- MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis
- (2019) Joost S. Vermaat et al. HAEMATOLOGICA
- Chromatin-Remodeled State in Lymphoma
- (2019) Yuxuan Liu et al. Current Hematologic Malignancy Reports
- Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma
- (2018) Weicheng Ren et al. BLOOD
- Genetics of diffuse large B-cell lymphoma
- (2018) Laura Pasqualucci et al. BLOOD
- The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel
- (2018) Wu Zhuang et al. Journal of Cancer
- Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening
- (2018) Viola Paradiso et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Genetic background and evolution of relapses in aggressive B-cell lymphomas
- (2017) Darius Juskevicius et al. HAEMATOLOGICA
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Genetic background and evolution of relapses in aggressive B-cell lymphomas
- (2017) Darius Juskevicius et al. HAEMATOLOGICA
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
- (2015) E Van Den Neste et al. BONE MARROW TRANSPLANTATION
- Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin
- (2015) Lijuan Deng et al. Oncotarget
- Survival analysis in hematologic malignancies: recommendations for clinicians
- (2014) J. Delgado et al. HAEMATOLOGICA
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
- (2013) Z. Zhou et al. BLOOD
- Clinical and prognostic role of annexin A2 in multiple myeloma
- (2012) A. Seckinger et al. BLOOD
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era
- (2010) Marita Ziepert et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More